Downloads

ALI, F. Y., ARMSTRONG, P. C., DHANJI, A. R., TUCKER, A. T., PAUL-CLARK, M. J., MITCHELL, J. A. & WARNER, T. D. 2009. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol, 29, 706-11. ALI, F. Y., DAVIDSON, S. J., MORAES, L. A., TRAVES, S. L., PAUL-CLARK, M., BISHOP-BAILEY, D., WARNER, T. D. & MITCHELL, J. A. 2006. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J, 20, 326-8. BORSCH-HAUBOLD, A. G., GHOMASHCHI, F., PASQUET, S., GOEDERT, M., COHEN, P., GELB, M. H. & WATSON, S. P. 1999. Phosphorylation of cytosolic phospholipase A2 in platelets is mediated by multiple stress-activated protein kinase pathways. Eur J Biochem, 265, 195-203. BORSCH-HAUBOLD, A. G., KRAMER, R. M. & WATSON, S. P. 1996. Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets. Biochem J, 318 ( Pt 1), 207-12. BYE, A. P., UNSWORTH, A. J., VAIYAPURI, S., STAINER, A. R., FRY, M. J. & GIBBINS, J. M. 2015. Ibrutinib Inhibits Platelet Integrin alphaIIbbeta3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen. Arterioscler Thromb Vasc Biol, 35, 2326-35. BYRD, J. C., FURMAN, R. R., COUTRE, S. E., FLINN, I. W., BURGER, J. A., BLUM, K. A., GRANT, B., SHARMAN, J. P., COLEMAN, M., WIERDA, W. G., JONES, J. A., ZHAO, W., HEEREMA, N. A., JOHNSON, A. J., SUKBUNTHERNG, J., CHANG, B. Y., CLOW, F., HEDRICK, E., BUGGY, J. J., JAMES, D. F. & O'BRIEN, S. 2013. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med, 369, 32-42. CHANG, C. C., LU, W. J., ONG, E. T., CHIANG, C. W., LIN, S. C., HUANG, S. Y. & SHEU, J. R. 2011. A novel role of sesamol in inhibiting NF-kappaB-mediated signaling in platelet activation. J Biomed Sci, 18, 93. COX, D. S., ALLRED, A., ZHOU, Y., INFANTE, J. R., GORDON, M. S., BENDELL, J., JONES, S., BURRIS, H., 3RD & ORFORD, K. 2015. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. Clin Pharmacol Drug Dev, 4, 287-94. FLAHERTY, K. T., INFANTE, J. R., DAUD, A., GONZALEZ, R., KEFFORD, R. F., SOSMAN, J., HAMID, O., SCHUCHTER, L., CEBON, J., IBRAHIM, N., KUDCHADKAR, R., BURRIS, H. A., 3RD, FALCHOOK, G., ALGAZI, A., LEWIS, K., LONG, G. V., PUZANOV, I., LEBOWITZ, P., SINGH, A., LITTLE, S., SUN, P., ALLRED, A., OUELLET, D., KIM, K. B., PATEL, K. & WEBER, J. 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med, 367, 1694-703. FLEVARIS, P., LI, Z., ZHANG, G., ZHENG, Y., LIU, J. & DU, X. 2009. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood, 113, 893-901. GAMBARYAN, S., KOBSAR, A., RUKOYATKINA, N., HERTERICH, S., GEIGER, J., SMOLENSKI, A., LOHMANN, S. M. & WALTER, U. 2010. Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex. J Biol Chem, 285, 18352-63. GARCIA, A., QUINTON, T. M., DORSAM, R. T. & KUNAPULI, S. P. 2005. Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets. Blood, 106, 3410-4. GARCIA, A., SHANKAR, H., MURUGAPPAN, S., KIM, S. & KUNAPULI, S. P. 2007. Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets. Biochem J, 404, 299-308. HIRATSUKA, T., SANO, T., KATO, H., KOMATSU, N., IMAJO, M., KAMIOKA, Y., SUMIYAMA, K., BANNO, F., MIYATA, T. & MATSUDA, M. 2017. Live imaging of extracellular signal-regulated kinase and protein kinase A activities during thrombus formation in mice expressing biosensors based on Forster resonance energy transfer. J Thromb Haemost, 15, 1487-1499. JIANG, F., JIA, Y. & COHEN, I. 2002. Fibronectin- and protein kinase C-mediated activation of ERK/MAPK are essential for proplateletlike formation. Blood, 99, 3579-84. KAISER, W. J., HOLBROOK, L. M., TUCKER, K. L., STANLEY, R. G. & GIBBINS, J. M. 2009. A functional proteomic method for the enrichment of peripheral membrane proteins reveals the collagen binding protein Hsp47 is exposed on the surface of activated human platelets. J Proteome Res, 8, 2903-14. KAMEL, S., HORTON, L., YSEBAERT, L., LEVADE, M., BURBURY, K., TAN, S., COLE-SINCLAIR, M., REYNOLDS, J., FILSHIE, R., SCHISCHKA, S., KHOT, A., SANDHU, S., KEATING, M. J., NANDURKAR, H. & TAM, C. S. 2015. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia, 29, 783-7. LEE LE, M., FEUN, L. & TAN, Y. 2014. A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma. Am J Case Rep, 15, 441-3. LEVADE, M., DAVID, E., GARCIA, C., LAURENT, P. A., CADOT, S., MICHALLET, A. S., BORDET, J. C., TAM, C., SIE, P., YSEBAERT, L. & PAYRASTRE, B. 2014. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood, 124, 3991-5. LI, Z., XI, X. & DU, X. 2001. A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin alpha IIbbeta3. J Biol Chem, 276, 42226-32. LONG, G. V., STROYAKOVSKIY, D., GOGAS, H., LEVCHENKO, E., DE BRAUD, F., LARKIN, J., GARBE, C., JOUARY, T., HAUSCHILD, A., GROB, J. J., CHIARION-SILENI, V., LEBBE, C., MANDALA, M., MILLWARD, M., ARANCE, A., BONDARENKO, I., HAANEN, J. B., HANSSON, J., UTIKAL, J., FERRARESI, V., KOVALENKO, N., MOHR, P., PROBACHAI, V., SCHADENDORF, D., NATHAN, P., ROBERT, C., RIBAS, A., DEMARINI, D. J., IRANI, J. G., SWANN, S., LEGOS, J. J., JIN, F., MOOKERJEE, B. & FLAHERTY, K. 2015. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, 386, 444-51. LORDKIPANIDZE, M., LOWE, G. C., KIRKBY, N. S., CHAN, M. V., LUNDBERG, M. H., MORGAN, N. V., BEM, D., NISAR, S. P., LEO, V. C., JONES, M. L., MUNDELL, S. J., DALY, M. E., MUMFORD, A. D., WARNER, T. D., WATSON, S. P., GENOTYPING, U. K. & PHENOTYPING OF PLATELETS STUDY, G. 2014. Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. Blood, 123, e11-22. LU, W. J., LIN, K. C., HUANG, S. Y., THOMAS, P. A., WU, Y. H., WU, H. C., LIN, K. H. & SHEU, J. R. 2014. Role of a Janus kinase 2-dependent signaling pathway in platelet activation. Thromb Res, 133, 1088-96. MALAVER, E., ROMANIUK, M. A., D'ATRI, L. P., POZNER, R. G., NEGROTTO, S., BENZADON, R. & SCHATTNER, M. 2009. NF-kappaB inhibitors impair platelet activation responses. J Thromb Haemost, 7, 1333-43. MAZHARIAN, A., ROGER, S., MAURICE, P., BERROU, E., POPOFF, M. R., HOYLAERTS, M. F., FAUVEL-LAFEVE, F., BONNEFOY, A. & BRYCKAERT, M. 2005. Differential Involvement of ERK2 and p38 in platelet adhesion to collagen. J Biol Chem, 280, 26002-10. MCNICOL, A. & JACKSON, E. C. 2003. Inhibition of the MEK/ERK pathway has no effect on agonist-induced aggregation of human platelets. Biochem Pharmacol, 65, 1243-50. MCNICOL, A., SHIBOU, T. S., PAMPOLINA, C. & ISRAELS, S. J. 2001. Incorporation of map kinases into the platelet cytoskeleton. Thromb Res, 103, 25-34. MORAES, L. A., PAUL-CLARK, M. J., RICKMAN, A., FLOWER, R. J., GOULDING, N. J. & PERRETTI, M. 2005. Ligand-specific glucocorticoid receptor activation in human platelets. Blood, 106, 4167-75. MORAES, L. A., SPYRIDON, M., KAISER, W. J., JONES, C. I., SAGE, T., ATHERTON, R. E. & GIBBINS, J. M. 2010. Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation. J Thromb Haemost, 8, 577-87. MORAES, L. A., SWALES, K. E., WRAY, J. A., DAMAZO, A., GIBBINS, J. M., WARNER, T. D. & BISHOP-BAILEY, D. 2007. Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood, 109, 3741-4. MORAES, L. A., UNSWORTH, A. J., VAIYAPURI, S., ALI, M. S., SASIKUMAR, P., SAGE, T., FLORA, G. D., BYE, A. P., KRIEK, N., DORCHIES, E., MOLENDI-COSTE, O., DOMBROWICZ, D., STAELS, B., BISHOP-BAILEY, D. & GIBBINS, J. M. 2016. Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets. Arterioscler Thromb Vasc Biol, 36, 2324-2333. NADAL-WOLLBOLD, F., PAWLOWSKI, M., LEVY-TOLEDANO, S., BERROU, E., ROSA, J. P. & BRYCKAERT, M. 2002. Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett, 531, 475-82. NAKASHIMA, S., CHATANI, Y., NAKAMURA, M., MIYOSHI, N., KOHNO, M. & NOZAWA, Y. 1994. Tyrosine phosphorylation and activation of mitogen-activated protein kinases by thrombin in human platelets: possible involvement in late arachidonic acid release. Biochem Biophys Res Commun, 198, 497-503. NEWTON, A. C. 2003. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J, 370, 361-71. PAPKOFF, J., CHEN, R. H., BLENIS, J. & FORSMAN, J. 1994. p42 mitogen-activated protein kinase and p90 ribosomal S6 kinase are selectively phosphorylated and activated during thrombin-induced platelet activation and aggregation. Mol Cell Biol, 14, 463-72. QUINTAS-CARDAMA, A., KANTARJIAN, H., RAVANDI, F., O'BRIEN, S., THOMAS, D., VIDAL-SENMACHE, G., WIERDA, W., KORNBLAU, S. & CORTES, J. 2009. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer, 115, 2482-90. RAY, L. B. & STURGILL, T. W. 1988. Insulin-stimulated microtubule-associated protein kinase is phosphorylated on tyrosine and threonine in vivo. Proc Natl Acad Sci U S A, 85, 3753-7. RICE, K. D., AAY, N., ANAND, N. K., BLAZEY, C. M., BOWLES, O. J., BUSSENIUS, J., COSTANZO, S., CURTIS, J. K., DEFINA, S. C., DUBENKO, L., ENGST, S., JOSHI, A. A., KENNEDY, A. R., KIM, A. I., KOLTUN, E. S., LOUGHEED, J. C., MANALO, J. C., MARTINI, J. F., NUSS, J. M., PETO, C. J., TSANG, T. H., YU, P. & JOHNSTON, S. 2012. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med Chem Lett, 3, 416-21. RONDINA, M. T., FREITAG, M., PLUTHERO, F. G., KAHR, W. H., ROWLEY, J. W., KRAISS, L. W., FRANKS, Z., ZIMMERMAN, G. A., WEYRICH, A. S. & SCHWERTZ, H. 2016. Non-genomic activities of retinoic acid receptor alpha control actin cytoskeletal events in human platelets. J Thromb Haemost, 14, 1082-94. ROSKOSKI, R., JR. 2012. MEK1/2 dual-specificity protein kinases: structure and regulation. Biochem Biophys Res Commun, 417, 5-10. ROSKOSKI, R., JR. 2017. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharmacol Res, 117, 20-31. RUSHWORTH, S. A., MACEWAN, D. J. & BOWLES, K. M. 2013. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med, 369, 1277-8. SPINELLI, S. L., CASEY, A. E., POLLOCK, S. J., GERTZ, J. M., MCMILLAN, D. H., NARASIPURA, S. D., MODY, N. A., KING, M. R., MAGGIRWAR, S. B., FRANCIS, C. W., TAUBMAN, M. B., BLUMBERG, N. & PHIPPS, R. P. 2010. Platelets and megakaryocytes contain functional nuclear factor-kappaB. Arterioscler Thromb Vasc Biol, 30, 591-8. SPYRIDON, M., MORAES, L. A., JONES, C. I., SAGE, T., SASIKUMAR, P., BUCCI, G. & GIBBINS, J. M. 2011. LXR as a novel antithrombotic target. Blood, 117, 5751-61. TAKAHASHI, R. H., CHOO, E. F., MA, S., WONG, S., HALLADAY, J., DENG, Y., ROONEY, I., GATES, M., HOP, C. E., KHOJASTEH, S. C., DRESSER, M. J. & MUSIB, L. 2016. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. Drug Metab Dispos, 44, 28-39. UNSWORTH, A. J., BYE, A. P., TANNETTA, D. S., DESBOROUGH, M. J. R., KRIEK, N., SAGE, T., ALLAN, H. E., CRESCENTE, M., YAQOOB, P., WARNER, T. D., JONES, C. I. & GIBBINS, J. M. 2017a. Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology. UNSWORTH, A. J., FLORA, G. D. & GIBBINS, J. M. 2018. Non-genomic effects of nuclear receptors: insights from the anucleate platelet. Cardiovasc Res, 114, 645-655. UNSWORTH, A. J., FLORA, G. D., SASIKUMAR, P., BYE, A. P., SAGE, T., KRIEK, N., CRESCENTE, M. & GIBBINS, J. M. 2017b. RXR Ligands Negatively Regulate Thrombosis and Hemostasis. Arterioscler Thromb Vasc Biol, 37, 812-822. ZHOU, Z., GUSHIKEN, F. C., BOLGIANO, D., SALSBERY, B. J., AGHAKASIRI, N., JING, N., WU, X., VIJAYAN, K. V., RUMBAUT, R. E., ADACHI, R., LOPEZ, J. A. & DONG, J. F. 2013. Signal transducer and activator of transcription 3 (STAT3) regulates collagen-induced platelet aggregation independently of its transcription factor activity. Circulation, 127, 476-485.